Idelalisib

Across CCLE and GDSC cell-line panels, response to Idelalisib is significantly associated with the mutation status of multiple genes, with BLOOD_Lymphoma cell lines showing a particularly strong set of associations.

The most reproducible Idelalisib response-associated genes across cancer lineages are DNAH9, MUC16, and TP53, each associated with drug response in up to 3 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The box plot shows the strongest observed association, Idelalisib response grouped by DNAH9 status in BLOOD_Lymphoma.

Mutation status biomarkers of Idelalisib response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Lymphoma	DNAH9 →	-3.169	-0.563	.011	.043	3	3
SOFT_TISSUE	MUC16 →	-1.584	-0.495	.029	.010	3	3
OVARY	TP53 →	-1.169	-0.403	.008	.010	3	3
LARGE_INTESTINE	FLG →	+1.000	+0.298	.046	.041	3	3
LUNG_SCLC	XIRP2 →	-1.977	-0.273	.025	.016	3	2
LUNG_NSCLC_LUAD	ADAMTS20 →	-2.951	-0.400	.025	.016	3	2

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Idelalisib response by DNAH9 status — BLOOD_Lymphoma

Explore this box plot interactively →